The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Time, location and function of hypoxia-inducible factors are critical to therapeutic tumour response
Open accessAbstract
Multiple lines of evidence confirm the strong association between the presence of hypoxia in solid tumours and poorer outcomes in patients with cancer resulting from both more aggressive tumour cell behaviour and impaired responses to therapy.[1 2][1] With well over 12 000 articles published in
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple experimental studies provide evidence that reducing or eliminating HIF-α subunit expression can provide therapeutic benefit , particularly in cancer models [270,271] (see Fig. 4).”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [271]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaśkiewicz, M., Moszyńska, A., Króliczewski, J., Cabaj, A., Bartoszewska, S., Charzyńska, A., Gebert, M., Dąbrowski, M., Collawn, J. F., & Bartoszewski, R. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00408-7 · Cited by 143
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
Research works printed but not linked: 7
- 10.1093/jnci/93.4.266 · DOI · Paper page
- 10.1016/j.radonc.2011.03.004 · DOI · Paper page
- Hu H , Chen Y , Tan S , et al . The research progress of Antiangiogenic therapy, immune therapy and tumor Microenvironment. Front Immunol 2022;13. doi:10.3389/fimmu.2022.802846 · DOI · Paper page
- Corrado, 2020, Hypoxia and HIF Signaling: one axis with divergent effects, Int J Mol Sci, 21, 5611, 10.3390/ijms21165611 · DOI
- 10.1016/j.yexcr.2017.03.008 · DOI
- Reiterer M , Colaço R , Emrouznejad P , et al . Acute and chronic hypoxia Differentially Predispose lungs for metastases. Sci Rep 2019;9. doi:10.1038/s41598-019-46763-y · DOI
- 10.1007/s00441-018-2801-6 · DOI
Cited by
Sorted by citations
HIF inhibition: Current strategies and clinical challenges
Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3
Metadata
- Authors
- Marignol, L., & Pugh, C. W.
- Affiliations
- Trinity College Dublin (IE)
- University of Oxford (GB)
- Corresponding author
- Marignol, Laure
- Venue
- BMJ Oncology
- Publisher
- BMJ
- Published
- 2024-02
- Volume
- 3
- Issue
- 1
- Pages
- e000290
- ISSN
- 2752-7948 (ISSN-L)
- PMC
- PMC11235017
- OpenAlex
- W4391430221
- Cited by
- 1
- References
- 2
- Citations by year
- 2025: 1
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- BMJ Oncology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- hypoxia-inducible factor, tumor hypoxia, solid tumors, treatment response, cancer prognosis, tumor microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
